• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED)
Conclusions: It seems that CME is being used to promote lisdexamfetamine for weight loss (a contraindicated use) and to highlight benefits of lisdexamfetamine while underplaying the risks.
Source: Journal of the American Board of Family Medicine - March 15, 2020 Category: Primary Care Authors: Jung, J., Fugh-Berman, A. Tags: Original Research Source Type: research

An Unusual Cause of Abdominal Pain in a Young, Hypertensive Female
Question: A 21-year-old woman of Indian descent presented with subacute left upper quadrant abdominal pain. The pain was sharp, severe, and elicited by food. She denied diarrhea, constipation, and weight loss. Her past medical history was significant for hypertension diagnosed as a teenager and ischemic stroke, attributed to Moya-Moya disease, and treated with stenting and bypass of the left middle cerebral and internal carotid arteries. Her medications included amlodipine, aspirin, and topiramate.
Source: Gastroenterology - January 17, 2018 Category: Gastroenterology Authors: Kevin L. Huang, Yih C. Lin, Kellee L. Oller Tags: Electronic Clinical Challenges and Images in GI Source Type: research

Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity
This article reviews recent literature in the field of Obesity Medicine and highlights important findings from clinical trials. Future directions in the pharmacologic management of obesity are presented along with new diabetes medications that promote weight loss and reduce cardiovascular mortality.
Source: Current Atherosclerosis Reports - May 14, 2016 Category: Cardiology Source Type: research

Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side‐Effect Profiles
ABSTRACT Pharmacotherapy directed toward reducing body weight may provide benefits for both curbing obesity and lowering the risk of obesity‐associated co‐morbidities. However, many weight loss medications have been withdrawn from the market due to serious adverse effects. Examples include pulmonary hypertension (aminorex), cardiovascular toxicity, e.g. flenfluramine‐induced valvopathy, stroke (phenylpropanolamine), excess non‐fatal cardiovascular events (sibutramine), and neuro‐psychiatric issues (rimonabant ‐ approved in Europe, but not in the US). This negative experience has helped mold the current drug dev...
Source: Diabetes, Obesity and Metabolism - March 1, 2016 Category: Endocrinology Authors: Andrew J. Krentz, Ken Fujioka, Marcus Hompesch Tags: REVIEW ARTICLE Source Type: research

Cardiovascular effects of current and future anti-obesity drugs.
Abstract The prevalence of obesity increases and is associated with increases in co-morbidities e.g. type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, several forms of cancer, depression, and may result in reduction of expected remaining lifespan. We have reviewed the adverse effects on the cardiovascular system of anti-obesity drugs now retracted from the market as well as the cardiovascular profile of current drugs and potential pathways which are considered for treatment of obesity. Fenfluramine, and sibutramine were withdrawn due to increased cardiovascular ...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U Tags: Curr Vasc Pharmacol Source Type: research

Pharmacotherapy of obesity: clinical treatments and considerations.
Abstract Obesity is a world-wide epidemic associated with significant morbidity and mortality which costs billions of dollars per year. The associated related conditions are many and include heart disease, stroke, type II diabetes mellitus, sleep apnea and certain types of cancer. Given that it is a multifactorial problem, the treatments must also address the numerous causes associated with the development of obesity. The neurohormonal regulation of feeding and energy is a complex system often necessitating modification through more than 1 pathway to achieve weight loss. Therefore, in addition to lifestyle changes...
Source: The American Journal of the Medical Sciences - April 1, 2013 Category: Journals (General) Authors: Holes-Lewis KA, Malcolm R, O'Neil PM Tags: Am J Med Sci Source Type: research

Acute Stroke in Young Women Taking Phentermine (P01.249)
CONCLUSIONS: We present here two patients with mild underlying cerebrovascular risk factors who presented with acute stroke after taking diet pills containing phentermine. The public should be aware of the possible association between stroke and phentermine. More long-term outcomes research is necessary to understand the safety of phentermine-containing diet pills. Patients with cerebrovascular risk factors should be cautious about using Phentermine containing diet pills.Disclosure: Dr. Smit has nothing to disclose. Dr. Cutting has received personal compensation for activities with F1000. Dr. Conners has nothing to disclos...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Smit, L., Cutting, S., Conners, J., Lee, V., Song, S. Tags: P01 Cerebrovascular Disease I Source Type: research